Clinical trials of germline gene editing: The exploitation problem
By Erik Malmqvist,
Bioethics
| 06. 14. 2021
Abstract
The birth of the world’s first genetically edited babies in 2018 provoked considerable ethical outrage. Nonetheless, many scientists and bioethicists now advocate the pursuit of clinical uses of human germline gene editing. Progress towards this goal will require research, including clinical trials where genetically edited embryos are implanted into a woman’s uterus, gestated, and brought to term. This paper argues that such trials would likely conflict with the fundamental research ethical requirement of non-exploitation. This is because they would expose people who are in a vulnerable situation to risks and burdens that are substantial and not obviously offset by compensating benefits. I consider how the potential for exploitation in such trials might be mitigated, arguing that a feasible and justifiable approach is not easily found. If this analysis is correct, there is a significant ethical obstacle on the path towards clinical use of human germline gene editing.
1 INTRODUCTION
In late 2018, He Jankui announced the birth of Lulu and Nana, the world’s first human beings born with an edited genome.1 The Chinese scientist had used the novel...
Related Articles
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Neel Shah, The Preprint | 04.11.2024
Years ago, I interviewed for a residency position at The Johns Hopkins Hospital in Baltimore. Standing before the domed Victorian building at the campus entrance, I couldn’t help but be in awe of the history of the place, the great...
By Eleanor Hayward and Joanna Crawford, The Times | 03.29.2024
Gazing out at the Mediterranean from an idyllic rocky mountaintop, Sophie Hermann announced to her half a million Instagram followers that she had decided to freeze her eggs. Since that post in August, the 37-year-old former Made in Chelsea star...